Abstract | UNLABELLED: Objective(s) : Although tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can selectively induce apoptosis in tumor cells, more than half of tumors including non-small cell lung cancer (NSCLC) exhibit TRAIL-resistance. The purpose of this study was to determine whether subtoxic-dose cisplatin and TRAIL could synergistically enhance apoptosis on NSCLC cells and investigate its underlying mechanisms. MATERIALS AND METHODS: RESULTS: Our results showed that NCI-H460 cells were sensitive to TRAIL, whereas A549 cells were resistant. However, subtoxic-dose cisplatin could enhance the both cells to TRAIL-mediated cell proliferation inhibition and apoptosis. The underlying mechanisms might be associated with the down-regulation of DcR2 and up-regulation of Caspase-8, Caspase-9 and Bax. CONCLUSION: Subtoxic-dose cisplatin could enhance both TRAIL- sensitive and TRAIL- resistant NSCLC cells to TRAIL-mediated apoptosis. These findings motivated further studies to evaluate such a combinatory therapeutic strategy against NSCLC in the animal models.
|
Authors | Xiaoyan Zhang, Jing Zhao, Wenyan Zhu, Hongfeng Gou, Dan Cao, Yu Yang, Ying Huang, Cheng Yi |
Journal | Iranian journal of basic medical sciences
(Iran J Basic Med Sci)
Vol. 16
Issue 5
Pg. 710-8
(May 2013)
ISSN: 2008-3866 [Print] Iran |
PMID | 23826494
(Publication Type: Journal Article)
|